TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03696511

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic miniscrew insertion
Description: orthodontic treatment using miniscrews as anchorage reinforcement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic miniscrew insertion
Description: orthodontic treatment using miniscrews as anchorage reinforcement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic miniscrew insertion
Description: orthodontic treatment using miniscrews as anchorage reinforcement
Study: NCT03995680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
Study: NCT04213781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HappyMed Video Glasses
Description: HappyMed allows the immersion of patients in films, cartoons or concerts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 0.1 µg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Sufentanil
Description: 0.1 µg/kg
Study: NCT02370004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistive Flexibility and Strength Training
Description: RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions.
Study: NCT00916058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 30 mg/m\^2 given on day 2 of melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 60 mg/m\^2 given on the 2nd day of melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 given on the 2nd day of melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 60 mg/m\^2 given on the 1st and 2nd day of melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
Study: NCT00278902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Study: NCT03798054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT03385265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIPPer Academy
Description: The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
Study: NCT01251081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extra high volume hemofiltration
Description: extra high volume hemofiltration (85 mL/kg/h, EHVHF)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: high volume hemofiltration
Description: high volume hemofiltration (50 mL/kg/h, HVHF)
Study: NCT03385265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
Study: NCT01539343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimicrobial Solution
Description: Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
Study: NCT03604874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intravenous infusion
Study: NCT01779700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: 0.5mg each day of 8 week cycle
Study: NCT05726565

Intervention type: OTHER
Intervention: multidisciplinary cardiac rehabilitation
Description: A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.

Intervention type: OTHER
Intervention: multidisciplinary cardiac rehabilitation
Description: A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
Study: NCT06413420

Intervention type: DRUG
Intervention: Sunosi (solriamfetol)
Description: Exposure to at least 1 dose of solriamfetol at any time during pregnancy.

Intervention type: DRUG
Intervention: Sunosi (solriamfetol)
Description: Exposure to at least 1 dose of solriamfetol at any time during pregnancy.

Intervention type: DRUG
Intervention: Other prescription wake-promoting medications or stimulants
Description: Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.

Intervention type: DRUG
Intervention: Other prescription wake-promoting medications or stimulants
Description: Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.

Intervention type: OTHER
Intervention: No treatment
Description: No treatment
Study: NCT04174989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)
Description: ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular fresh-frozen plasma (not treated)
Description: Regular fresh-frozen plasma (not treated)
Study: NCT03964246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Meditation (CM) intervention
Description: 10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Psychoeducation
Description: The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]
Study: NCT03855631

Intervention type: GENETIC
Intervention: Intervention on primary cultured cells
Description: The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
Study: NCT04582435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Icodec
Description: Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
Study: NCT02667223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1: bococizumab 150 mg + rHuPH20
Description: bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2: bococizumab 300 mg
Description: bococizumab 300 mg administered SC to healthy volunteers
Study: NCT01779700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet each day of 8 week cycle
Study: NCT02667223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3: bococizumab 300 mg + rHuPH20
Description: bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 5: bococizumab 450 mg + rHuPH20
Description: bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 4: bococizumab 300 mg + rHuPH20
Description: bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
Study: NCT03042377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-Visit Retreatment
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-Visit-Calcium Hydroxide
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-Visit-Corticosteroid Paste
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-Visit-Antibiotic Paste
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
Study: NCT01702376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban 100 mg
Description: Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
Study: NCT00597363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neptune P.A.D. (R)
Description: The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional manual compression
Description: The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
Study: NCT01151735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-1-esterase
Description: 1000 units of C-1-esterase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-1-esterase
Description: 1500 units of C-1-esterase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03738501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy with SET
Description: Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
Study: NCT00827424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling by applying a modified PACE protocol
Description: Lifestyle counseling by applying a modified PACE protocol to obese Arab women
Study: NCT02705495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture.
Study: NCT03738501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
Study: NCT01317537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic personal health record
Study: NCT03390478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Intervention Group
Description: Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
Study: NCT01259076

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: Undergo MRI at baseline and 1 year later.

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: Undergo MRI at baseline and 1 year later.
Study: NCT02705495

Intervention type: DRUG
Group type: OTHER
Intervention: Cranberry products
Description: Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry products
Description: Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
Study: NCT02508402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two milliliters of normal saline given to placebo group .
Study: NCT02835807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Chat including Indoor Tanning
Description: Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Chat excluding Indoor Tanning
Description: In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
Study: NCT03552653

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitafusion Extra Strength Vitamin D
Description: Monitor Vitamin D blood levels

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitafusion Extra Strength Vitamin D
Description: Monitor Vitamin D blood levels